Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world incidence of bleeding events in patients with chronic lymphocytic leukemia treated with acalabrutinib +/- obinutuzumab and requiring direct oral anticoagulation

Klaus Fenchel, Eyck von der Heyde, Matthias Zaiss et al. Nov 03, 2025 pp. 2724-2724 10.1182/blood-2025-2724

Abstract Background: A significant proportion of patients (pts) with Chronic Lymphocytic Leukemia (CLL) have cardiovascular comorbidities re...

Inclusive practices for safe and equitable donor assessment

Warren Fingrut, Eefke van Eerden, Terrie Foster et al. Nov 03, 2025 pp. 2648-2648 10.1182/blood-2025-2648

Abstract Background: Guidance is needed to optimize the recruitment, verification typing (VT) and workup of donors from vulnerable populatio...

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

Tarang Sharma, Maday Galeana Figueroa, Ravi Shah et al. Nov 03, 2025 pp. 4108-4108 10.1182/blood-2025-4108

Abstract Chimeric antigen receptor (CAR) T cell mediated trogocytosis (CMT) involves the transfer of the CAR binding antigen to the surface...

Time toxicity in ALL: Quantifying home days among adults with acute lymphoblastic leukemia

Daniel Richardson, Alexis Wardell, Christopher Wanjiku et al. Nov 03, 2025 pp. 6332-6332 10.1182/blood-2025-6332

Abstract Background: Treatment-related time toxicity, the burden of time to receive medical care, is increasingly recognized as an important...

Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure

Joseph Shatzel, Andrew Kuykendall, Aniket Bankar et al. Nov 03, 2025 pp. 5587-5587 10.1182/blood-2025-5587

Abstract Background: Patients with polycythemia vera (PV) are at increased risk of developing other non-PV malignancies, including skin canc...

Effect of graft cellular content on outcomes in HLA mismatched hematopoietic cell transplantation using post-transplant cyclophosphamide

Remy Dulery, Sandra Lee, Sarah Nikiforow et al. Nov 03, 2025 pp. 4260-4260 10.1182/blood-2025-4260

Abstract Background Since the introduction of post-transplant cyclophosphamide (PTCY) for graft versus host disease (GVHD) prophylaxis, the...

A multifunctional nanoplatform for ferroptosis inducing/chemo/photothermal therapy  enhances therapeutic effect and prevents adverse gastrointestinal reaction of methotrexate

Mengyao Wang, Qingya Liu, Zhiyong Qian et al. Nov 03, 2025 pp. 6107-6107 10.1182/blood-2025-6107

Abstract Backgrounds: Methotrexate (MTX) is pivotal in treating aggressive lymphomas. Recent studies show MTX not only interferes with DNA s...

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Timothy Hughes, Jorge Cortés, Jennifer Vaughn et al. Nov 03, 2025 pp. 5549-5549 10.1182/blood-2025-5549

Abstract Introduction Long-term CML treatment (Tx) requires assessing adverse event (AE) burden over time to optimize safety, tolerability,...

Machine learning models improve survival prediction in DLBCL: Analysis from the goya trial

Shuna Yao, Zian Lin, Bo Yang et al. Nov 03, 2025 pp. 3564-3564 10.1182/blood-2025-3564

Abstract Background: The International Prognostic Index (IPI) remains widely used for risk stratification in diffuse large B-cell lymphoma (D...

LDB1-dependent enhancer networks drive high-risk transcriptional programs in T-cell acute lymphoblastic leukemia

Rahul Bhansali, Juan Long, Petri Pölönen et al. Nov 03, 2025 pp. 3251-3251 10.1182/blood-2025-3251

Abstract In T-cell acute lymphoblastic leukemia (T-ALL), LMO2 (Lim domain only 2) is frequently overexpressed due to chromosomal translocati...

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

Chen Mei, Guifang Ouyang, Yanjuan Lin et al. Nov 03, 2025 pp. 492-492 10.1182/blood-2025-492

Abstract Background: Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by ineffective hematopoiesis, per...

A real-world experience of axicabtagene ciloleucel CAR-T in refractory/relapsed B-cell lymphoma from a tertiary center in Saudi Arabia

Alaa Eldein Yahia, Bilal Albtoosh, Abdullah Alsakkaf et al. Nov 03, 2025 pp. 7236-7236 10.1182/blood-2025-7236

Abstract Introduction: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of relapse...

Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics

Sebastiano Rontauroli, Chiara Carretta, Matteo Bertesi et al. Nov 03, 2025 pp. 3750-3750 10.1182/blood-2025-3750

Abstract Myelofibrosis (MF) originates from the acquisition of somatic mutations in hematopoietic stem and progenitor cells (HSPCs). MF driv...

The ‘αO2-PRBCThal’ trial on the use of hemanext One® for blood transfusion support transfusion-dependent thalassemia

Polyxeni Delaporta, Efthalia-Faidra Agiomavriti-Stephanopoulou, Elena Chatzikalil et al. Nov 03, 2025 pp. 8224-8224 10.1182/blood-2025-8224

Abstract Introduction: Patients with transfusion dependent thalassemia (TDT) are regularly transfused every two to four weeks. Red blood cel...

BRM/BRG1 is a novel therapeutic target in ZNF384-rearranged mixed phenotype acute leukemia

Clara Libbrecht, Chao-Jen Wong, Gabe Boyle et al. Nov 03, 2025 pp. 5088-5088 10.1182/blood-2025-5088

Abstract Mixed Phenotype Acute Leukemia (MPAL) is an understudied high-risk leukemia with poor outcomes. Patients have been historically exc...

Cost-effectiveness of hydroxyurea for children with sickle cell disease in sub-saharan Africa: A discrete event simulation model to inform policy and government planning

Patrick McGann, Donald Ayers, Lydia Musula et al. Nov 03, 2025 pp. 2590-2590 10.1182/blood-2025-2590

Abstract Background Sickle cell disease (SCD) is a highly common inherited disorder affecting more than 500,000 infants born each year, prim...

CLL with t(11;14)(q13;q32) or t(14:18)(q32:q21) –­­ is this CLL or lymphoma?

Alessandro Baldi, Wencke Walter, Anna Stengel et al. Nov 03, 2025 pp. 2114-2114 10.1182/blood-2025-2114

Abstract Background: The IGH rearrangements resulting from t(11;14)(q13;q32) and t(14;18)(q32;q21) typically characteriz...

Acquired FVIII deficiency in the setting of prior mechanical mitral valve replacement: A delicate balance of competing hemorrhagic and thrombotic risks

Akshit Chitkara, Trishya Srinivasan, Nathaniel Kuhrt et al. Nov 03, 2025 pp. 6640-6640 10.1182/blood-2025-6640

Abstract Introduction: Acquired Factor VIII (FVIII) deficiency, also known as acquired hemophilia A, is a rare and letha...

Age-related differences in presentation among pediatric, adolescent, and young adults with mixed cellularity vs. nodular sclerosis histology Hodgkin lymphoma on Children's oncology group treatment and registry trials

Mallorie Heneghan, Lindsay Renfro, Yue Wu et al. Nov 03, 2025 pp. 1849-1849 10.1182/blood-2025-1849

Abstract Introduction: Classic Hodgkin lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA; 15-39 years [y]...

A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era

Jahanzaib Khwaja, Amy Kirkwood, Paolo Milani et al. Nov 03, 2025 pp. 577-577 10.1182/blood-2025-577

Abstract Background: Systemic AL amyloidosis is an incurable disorder caused by misfolded light chain fibrils. Survival is determined by the...

Organ-based classification and risk-stratified outcomes in 568 east Asian patients with chronic active epstein-barr virus infection: A multicenter retrospective cohort study

Xinran Wang, Hui Luo, Di Wang et al. Nov 03, 2025 pp. 564-564 10.1182/blood-2025-564

Abstract Background: Chronic active Epstein-Barr virus infection (CAEBV) is a rare and potentially fatal lymphoproliferative disorder charac...

Diagnostic delays and misdiagnosis patterns in paroxysmal nocturnal hemoglobinuria

Adam Bowen, Miller Lantis, Dania Baraka et al. Nov 03, 2025 pp. 6433-6433 10.1182/blood-2025-6433

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder characterized by complement-mediat...

Mortality trends and disparities in purpura and related hemorrhagic conditions in the elderly population in the United States from 1999 to 2023: A CDC wonder databaseanalysis

Ahmed Raza, Muhammad Ali, Anas nasir et al. Nov 03, 2025 pp. 6580-6580 10.1182/blood-2025-6580

Abstract Introduction: Purpura and related hemorrhagic conditions are a spectrum of bleeding disorders consisting of various types of purpur...

Achieving JAK2V617F vaf <20% is associated with prolonged event-free survival in polycythemia vera: A milestone of molecular response

Franco Castillo Tokumori, Ghaith Abu-Zeinah, Katie Erdos et al. Nov 03, 2025 pp. 5575-5575 10.1182/blood-2025-5575

Abstract Background:In chronic myeloid leukemia (CML), absolute BCR-ABL molecular thresholds serve as validated milestones to predict long-t...

MYC rearrangements with immunoglobulin genes as an independent prognostic factor of progression-free survival in newly diagnosed patients

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Kyle Langford et al. Nov 03, 2025 pp. 361-361 10.1182/blood-2025-361

Abstract Introduction: MYC rearrangement (MYC-R), especially those involving the immunoglobulin loci (IGL, IGH, and IGK), are drivers of MM...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page